{
    "organizations": [],
    "uuid": "374b0e5673d50e50236bbf5e3a8cffa9a037b4cf",
    "author": "",
    "url": "https://www.reuters.com/article/brief-european-chmp-adopts-positive-opin/brief-european-chmp-adopts-positive-opinion-for-gileads-biktarvy-idUSFWN1S40YE",
    "ord_in_thread": 0,
    "title": "BRIEF-European CHMP Adopts Positive Opinion For Gilead's Biktarvy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 27, 2018 / 10:38 AM / Updated 10 minutes ago BRIEF-European CHMP Adopts Positive Opinion For Gilead's Biktarvy Reuters Staff 1 Min Read\nApril 27 (Reuters) - Gilead Sciences Inc:\n* EUROPEAN CHMP ADOPTS POSITIVE OPINION FOR GILEAD’S BIKTARVY® (BICTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE) Source text for Eikon: Further company coverage:",
    "published": "2018-04-27T13:37:00.000+03:00",
    "crawled": "2018-04-27T13:57:41.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "chmp",
        "adopts",
        "positive",
        "opinion",
        "gilead",
        "biktarvy",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "gilead",
        "science",
        "inc",
        "european",
        "chmp",
        "adopts",
        "positive",
        "opinion",
        "gilead",
        "bictegravir",
        "emtricitabine",
        "tenofovir",
        "alafenamide",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}